Clinical trials: Anticoagulant
Venous Thrombosis, Pulmonary Embolism
Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure
Blood clots in the leg veins, known as deep vein thrombosis, are important because they may travel to the lung (known as pulmonary embolism) and cause death. Blood clots are treated with blood thinners, or anticoagulants.
- Trial name
- NCT00186745
- Testing
- Tinzaparin
- Where
- Canada
- Volunteers
- 148 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Venous Thromboembolic Disease
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease share common risk factors and frequently coexist in the same patients.
- Trial name
- BAT-VTE (NCT05627375)
- Testing
- Full-dose anticoagulant therapy (AC), Antiplatelet therapy (AP)
- Where
- 28 sites in France
- Volunteers
- 1,400 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
An anticoagulation therapy is a critical treatment to prevent thromboembolism in non-valvular AF (NVAF) patients. Warfarin, a vitamin K antagonist, is the first oral anticoagulant approved for the treatment for prevention of…
- Trial name
- CER3 (NCT03570047)
- Where
- Japan
- Volunteers
- 73,989 people
- Sponsor
- Pfizer
Congenital Heart Defects, Atrial Fibrillation
NOACs for Atrial Tachyarrhythmias in Congenital Heart Disease
Rationale: Adult patients with congenital heart disease (CHD) with atrial tachyarrhythmias need to be anticoagulated. It is not known whether non-vitamin K antagonist oral anticoagulants (NOAC) in this patient group are efficient…
- Conditions
- Congenital Heart Defects, Atrial Fibrillation, Ectopic Atrial Tachycardia
- Trial name
- NOTE (NCT02928133)
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Atrial Fibrillation
Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Pilot
The proposed PAUSE-2 RCT study is the logical next step to the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study, which was completed on August 31, 2018.
- Trial name
- PAUSE2rctP (NCT04192552)
- Testing
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Where
- 3 sites in Canada
- Volunteers
- 201 people
- Sponsor
- McMaster University
Healthy Volunteers
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
- Trial name
- NCT03551743
- Testing
- PRT064445/Edoxaban
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Non-Valvular Atrial Fibrillation
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin…
- Trial name
- ARISTOPHANES (NCT03087487)
- Where
- United States
- Volunteers
- 466,991 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
This study is a retrospective, observational, nationwide population-based cohort study utilizing the South Korea's Health Insurance and Review Assessment Service (HIRA) database.
- Trial name
- NCT05022563
- Testing
- Parenteral anticoagulant, Warfarin, Apixaban
- Where
- 2 sites in South Korea
- Volunteers
- 55,759 people
- Sponsor
- Pfizer
Cardiovascular Diseases
Antithrombotics' Therapeutic Optimization in Hospitalized Patients Using Physiologically- and Population-based Pharmacokinetic Modeling
The main goal of the OptimAT study main goal is to validate a PBPK model for 3 direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) and 3 P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) in hospitalized patients.
- Trial name
- OptimAT (NCT03477331)
- Where
- Switzerland
- Volunteers
- 444 people
- Sponsor
- University Hospital, Geneva
Venous Thromboembolism, Deep Vein Thrombosis
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
Pregnant women with a prior history of venous thromboembolism (VTE) are at increased risk of recurrent VTE. Current guidelines assessing the role of prophylaxis in pregnant women with prior VTE are based primarily on expert…
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- ROCITP2 (NCT01357941)
- Where
- 2 sites in Canada
- Volunteers
- 203 people
- Sponsor
- Hamilton Health Sciences Corporation
Venous Thrombosis, Neoplasms
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
The purpose of this study is to determine the optimal duration of anticoagulation therapy (3 months versus 12 months) with direct oral anticoagulant (edoxaban) for isolated distal deep vein thrombosis.
- Conditions
- Venous Thrombosis, Neoplasms, Anticoagulant
- Trial name
- ONCO DVT (NCT03895502)
- Testing
- 12-month Edoxaban, 3-month Edoxaban
- Where
- Japan
- Volunteers
- 605 people
- Sponsor
- Takeshi Morimoto
Venous Thromboembolism
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
- Trial name
- VTE (NCT04041843)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
COVID, Coronavirus Infection
A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic
Coagulopathy of COVID-19 afflicts approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death.
- Conditions
- COVID, Coronavirus Infection, Severe Acute Respiratory Syndrome, Thromboembolism, Venous
- Trial name
- RAPID-BRAZIL (NCT04444700)
- Testing
- Therapeutic anticoagulation
- Where
- Brazil
- Volunteers
- 465 people
- Sponsor
- University of Sao Paulo General Hospital
Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)
DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial
People with atrial fibrillation who have a stroke while receiving a DOAC are at increased risk of experiencing another stroke. Physicians do not know the best medication to prevent another stroke in this group of people.
- Trial name
- SWITCH-AF (NCT07011095)
- Testing
- VKA, Direct Oral Anticoagulant (DOAC)
- Volunteers
- 100 people
- Sponsor
- Population Health Research Institute
Extracorporeal Membrane Oxygenation
When Heparin Stopped for Anticoagulation During ECMO Decannulation
Heparin (regular or unfractionated heparin, not low molecular weight heparin) is given as a bolus (50-100 units per kilogram) at the time of extracorporeal membrane oxygenation(ECMO) cannulation, and by continuous infusion during…
- Trial name
- NCT05239637
- Testing
- Heparin stopped before ECMO decannulation, Heparin reduced after ECMO decannulation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Zhengzhou University
Periprocedural Complication
Periprocedural Direct Oral Anticoagulant Management
Direct oral anticoagulants (DOAC) are a new drug group that has been approved for chronic anticoagulation of patients in atrial fibrillation or suffering acute thrombosis, between others.
- Trial name
- RA-ACOD (NCT03182218)
- Testing
- Direct oral anticoagulant
- Where
- 30 sites in Spain
- Volunteers
- 1,100 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Endoscopic Ultrasonography-guided Fine Needle Aspiration
EUS-FNA for Patients Taking Anticoagulants Without Heparin Bridge
To evaluate the feasibility of EUS-FNA for patients taking anticoagulants without heparin bridge.
- Trial name
- NCT02977650
- Testing
- Endoscopic ultrasonography-guided fine needle aspiration
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Hokkaido Pancreatobiliary Endoscopic Intervention Study Group
Atrial Fibrillation
Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..
Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation who are treated with direct oral anticoagulants (DOACs) to evaluate the clinical course (occurrence of…
- Trial name
- NCT04297150
- Testing
- Apixaban, Edoxaban, Rivaroxaban
- Where
- 6 sites in Spain
- Volunteers
- 700 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Healthy
Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With Anticoagulants
The study will assess the distribution and variability of whole blood clotting time (WBCT) measurement in human blood collected from healthy volunteers that is untreated and spiked with predetermined concentrations of edoxaban or…
- Trial name
- NCT03296982
- Testing
- Blood drawn by direct venipuncture, edoxaban, Enoxaparin
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)
Precision Antithrombotic Therapy
The goal of this observational study is to systematically analyze the relationship between trough/peak concentrations of novel oral anticoagulants (NOACs) and antiplatelet drugs with clinical events, aiming to provide high-level…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE), MI(Myocardial Infarction), Ischemic Stroke
- Trial name
- NCT07654634
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- The Third Xiangya Hospital of Central South University